Studies
Current Endometriosis Research
Understanding endometriosis requires access to reliable, up-to-date research. This Study Page is for those who want to explore the evidence behind current knowledge. It is a curated, searchable research index for endometriosis-specific publications and ongoing clinical studies, and invites you to visually explore the interrelations between research topics that may not be obvious at first glance.
Do you want to:
Studies you can join
Clinical studies seeking participants
Currently recruiting
ENDOVA: Vagus Nerve Stimulation in Symptomatic Endometriosis
MedUni Vienna is recruiting for ENDOVA, a prospective, double-blind, sham-controlled, randomized pilot study evaluating whether gentle auricular vagus nerve stimulation with the VIVO® class IIa medical device can improve quality of life and pain in people with symptomatic endometriosis. Participation lasts approximately 4.5 months and includes 6 weeks of device use, weekly appointments in Vienna during the device phase, and an electronic pain diary throughout the study. Basic criteria include age 18-51, surgically confirmed endometriosis or diagnosis by ultrasound/MRI, menstrual pain or chronic lower abdominal pain, and no current hormonal endometriosis therapy; people with a pacemaker cannot participate.
ELECTRE
A single-center randomized study evaluating the efficacy and tolerability of a transcutaneous electrical nerve stimulation (TENS) device for managing endometriosis-associated pelvic pain. The study compares conventional TENS with microstimulation TENS and is recruiting adult women with endometriosis and/or adenomyosis diagnosed by imaging and/or histology.
EndoSolve
OnaWave Medical is developing a novel, non-invasive and painless method for faster diagnosis of endometriosis through analysis of subtle bioelectric rhythms in the pelvis. Built on research from University of Galway and supported by the European Innovation Council.
Recruitment ended - results pending
NOVA – Vipoglanstat (Phase 2)
A randomized, double-blind, placebo-controlled Phase 2 trial by Swedish biotech Gesynta Pharma investigating Vipoglanstat, a non-hormonal and non-opioid compound, for endometriosis-associated pain. Approximately 190 women aged 18–45 are being enrolled across multiple European centers to evaluate efficacy, safety, and optimal dosing.
Endogreet
A potential non-hormonal treatment approach using Tigovit, a green tea extract, in a randomized, double-blind, placebo-controlled study at MedUni Vienna. Green tea extract has shown promise in reducing both pain and inflammation around endometriosis lesions.
IMAGENDO
Imaging study aiming to reduce endometriosis diagnosis time through improved imaging analysis. Participants needed pelvic MRI or transvaginal ultrasound examinations.
ENDOFLEX
A MedUni Vienna study investigating Flexofytol, a curcumin extract preparation, as a potential non-hormonal approach for endometriosis-associated pain. The rationale was based on the inflammatory component of endometriosis symptoms and prior clinical data suggesting anti-inflammatory and antioxidant pain-relief effects of curcumin preparations in osteoarthritis.
Published Endometriosis Research
Browse curated endometriosis publications across various categories. Each entry links back to the original publication source.
14 publications
Review synthesizing evidence on how disorders of gut-brain interaction affect women differently across the lifespan, including comorbid conditions like endometriosis. The authors call for clinical trials that account for hormonal influences on symptoms and treatment outcomes, inclusion of sex-specific comorbidities, and cross-disciplinary trial designs addressing overlapping symptoms between gut-brain disorders and gynecological conditions.
Dec 26, 2025
Bioinformatics study combining gene expression data from the Turku Endometriosis Database with Global Burden of Disease 2021 data. Identified upregulated genes (FOS, DES) and pain-related genes (NGF, BSN). Women with endometriosis showed the highest rates of total years lived with disability (19.98%), with anxiety contributing 17.21% and major depression 8.12%. The identified genetic markers related to pain provide a biological basis for the profound physical suffering, while the DALYs and YLDs data quantify the devastating impact on mental health - underscoring the importance of adopting a holistic, psychosomatic approach to managing endometriosis.
Dec 23, 2025
Women with endometriosis show significantly elevated risks for depression, anxiety disorders, and substance use disorders. Notably, postoperative hormonal therapy did not reduce psychiatric risk, highlighting the need for integrated gynecologic and psychological care.
Nov 21, 2025
Analysis of over 40,000 endometriosis patients across six University of California medical centers identified hundreds of significantly associated conditions including genitourinary disorders, neoplasms, and autoimmune diseases. Clustering analyses revealed distinct patient subpopulations with psychiatric and autoimmune comorbidity patterns.
Aug 19, 2025
This review explores how endometriosis elevates cardiovascular disease risk through chronic systemic inflammation, endothelial dysfunction, oxidative stress, and metabolic disturbances. The authors emphasize that a multidisciplinary approach involving gynecologists, cardiologists, and primary care providers is essential for managing these interconnected conditions.
Jun 8, 2025
Systematic review and meta-analysis of seven studies involving over 1.4 million participants examining cardiovascular risk in women with endometriosis. Women with endometriosis showed significantly elevated risks for cerebrovascular disease (HR 1.19), ischemic heart disease (HR 1.35), major adverse cardiovascular events (HR 1.15), and arrhythmias (HR 1.21). No significant association was found with heart failure or all-cause mortality.
May 23, 2025